Related Experiment Video
Updated: Dec 22, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer
Jiahao Liu1, Xiaofei Jiao1, Qinglei Gao1
1Department of Gynecological Oncology, Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Neoadjuvant chemotherapy (NACT) has been regarded a standard treatment for advanced ovarian cancers for decades. Among patients who are poor candidates for primary debulking surgery (PDS), NACT is likely their only option in clinical practice. However, NACT failed to show any survival benefit in the reported randomized controlled trials (RCTs) and the meta-analyses, compared with PDS. This phenomenon raises concerns over the unfavorable influence of NACT, that is, the potential risk of inducing platinum resistance. In this review, we reveal the risk of NACT-related platinum resistance by summarizing the experimental and clinical evidence and discuss new attempts to avoid this phenomenon.
More Related Videos
04:07Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Related Concept Videos
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...